{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:29:01Z","timestamp":1786645741831,"version":"build-2736575974"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Modest body weight reduction can greatly improve many health-related outcomes. In the SURMOUNT clinical trial program, once-weekly tirzepatide resulted in substantial body weight reductions in people with obesity, without and with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This post-hoc analysis assessed the proportion of participants achieving body weight reduction thresholds (\u22655%,\u2009\u226510%,\u2009\u226515%), systolic blood pressure reduction \u22655 mmHg, and non-high-density lipoprotein cholesterol (non-HDL-C) &lt;130 mg\/dL with tirzepatide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants from SURMOUNT 1\u20134 randomized to tirzepatide or placebo with valid baseline and \u22651 non-missing post-baseline body weight, systolic blood pressure and non-HDL-C measurements were included in this analysis. The proportion of participants achieving the triple endpoints was assessed at the primary endpoint of each study (Week 72 for SURMOUNT-1, SURMOUNT-2 and SURMOUNT-3 and Week 88 for SURMOUNT-4).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across the trials, 32\u201338% vs 2\u20138% of tirzepatide-treated vs placebo-treated participants achieved \u22655% body weight reduction, systolic blood pressure reduction \u22655 mmHg, and non-HDL-C\u2009&lt;130 mg\/dL, 28\u201337% vs 1\u20135%, respectively, achieved the triple endpoint with the\u2009\u226510% body weight reduction threshold, and 22\u201334% vs 1\u20133%, respectively, achieved the triple endpoint with the\u2009\u226515% body weight reduction threshold. The between-treatment odds ratios for these proportions across the trials, were statistically significant (all p&lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this post hoc analysis of SURMOUNT, more participants achieved the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction \u22655 mmHg and non-HDL-C\u2009&lt;130 mg\/dL with tirzepatide vs placebo. Studies evaluating the potential cardiovascular benefits of tirzepatide are ongoing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0345032","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T17:34:11Z","timestamp":1786642451000},"page":"e0345032","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction \u22655 mmHg and non-HDL cholesterol &lt;130 mg\/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1604-2593","authenticated-orcid":true,"given":"Naveed","family":"Sattar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshmi","family":"Srinath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis-Emilio","family":"Garc\u00eda-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrisanthi A.","family":"Karanikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arian","family":"Plat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"issue":"10431","key":"pone.0345032.ref001","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"pone.0345032.ref002","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"M Bl\u00fcher","year":"2019","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"pone.0345032.ref003","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1514009","article-title":"Mechanisms, pathophysiology, and management of obesity","volume":"376","author":"SB Heymsfield","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0345032.ref004","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13216","article-title":"The impact of obesity on immune response to infection: plausible mechanisms and outcomes","volume":"22","author":"G Muscogiuri","year":"2021","journal-title":"Obes Rev"},{"issue":"10","key":"pone.0345032.ref005","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-2667(18)30139-7","article-title":"Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study","volume":"3","author":"ST Nyberg","year":"2018","journal-title":"Lancet Public Health"},{"issue":"10046","key":"pone.0345032.ref006","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0140-6736(16)30175-1","article-title":"Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents","volume":"388","author":"Global BMI Mortality Collaboration","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"pone.0345032.ref007","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"GBD 2015 Obesity Collaborators","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0345032.ref008","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S2213-8587(22)00033-X","article-title":"Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study","volume":"10","author":"M Kivim\u00e4ki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"pone.0345032.ref009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"WT Garvey","year":"2016","journal-title":"Endocrine Practice"},{"issue":"7","key":"pone.0345032.ref010","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"RR Wing","year":"2011","journal-title":"Diabetes Care"},{"issue":"3","key":"pone.0345032.ref011","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"AM Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"10402","key":"pone.0345032.ref012","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"WT Garvey","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"pone.0345032.ref013","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"TA Wadden","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"pone.0345032.ref014","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"LJ Aronne","year":"2024","journal-title":"JAMA"},{"issue":"3","key":"pone.0345032.ref015","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/oby.23652","article-title":"Trends in obesity prevalence and cardiometabolic risk factor control in US adults with diabetes, 1999-2020","volume":"31","author":"G Hu","year":"2023","journal-title":"Obesity"},{"issue":"5","key":"pone.0345032.ref016","first-page":"846","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials","volume":"48","author":"MMY Lee","year":"2025","journal-title":"Diabetes Care"},{"issue":"10285","key":"pone.0345032.ref017","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"pone.0345032.ref018","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"F Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"pone.0345032.ref019","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"63","author":"MD Jensen","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"pone.0345032.ref020","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"TM Powell-Wiley","year":"2021","journal-title":"Circulation"},{"issue":"4","key":"pone.0345032.ref021","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2337\/dci23-0041","article-title":"Cardiovascular and kidney risks in individuals with type 2 diabetes: contemporary understanding with greater emphasis on excess adiposity","volume":"47","author":"N Sattar","year":"2024","journal-title":"Diabetes Care"},{"issue":"7","key":"pone.0345032.ref022","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1038\/s41591-024-03013-7","article-title":"What the SELECT trial of semaglutide means for clinicians","volume":"30","author":"N Sattar","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"pone.0345032.ref023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121993","article-title":"Intentional weight loss and all-cause mortality: a meta-analysis of randomized clinical trials","volume":"10","author":"SB Kritchevsky","year":"2015","journal-title":"PLoS One"},{"issue":"24","key":"pone.0345032.ref024","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes","volume":"393","author":"SJ Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"pone.0345032.ref025","article-title":"Estimating the true MACE benefits from tirzepatide in SURPASS-CVOT using an imputed placebo analysis of REWIND","author":"N Sattar","year":"2026","journal-title":"Diabetes Care"},{"issue":"2","key":"pone.0345032.ref026","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0091-7435(87)90087-9","article-title":"Incidence and precursors of hypertension in young adults: the Framingham Offspring Study","volume":"16","author":"RJ Garrison","year":"1987","journal-title":"Prev Med"},{"issue":"1","key":"pone.0345032.ref027","doi-asserted-by":"crossref","first-page":"80","DOI":"10.21037\/gs.2019.12.03","article-title":"Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery","volume":"9","author":"OA Shariq","year":"2020","journal-title":"Gland Surg"},{"issue":"3","key":"pone.0345032.ref028","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s13679-023-00518-z","article-title":"Obesity and dyslipidemia: a review of current evidence","volume":"12","author":"J Vekic","year":"2023","journal-title":"Curr Obes Rep"},{"key":"pone.0345032.ref029","doi-asserted-by":"crossref","first-page":"117312","DOI":"10.1016\/j.atherosclerosis.2023.117312","article-title":"Non-HDL-cholesterol in dyslipidemia: review of the state-of-the-art literature and outlook","volume":"383","author":"V Raja","year":"2023","journal-title":"Atherosclerosis"},{"issue":"7","key":"pone.0345032.ref030","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/CIRCULATIONAHA.119.041149","article-title":"Comparison of conventional lipoprotein tests and apolipoproteins in the prediction of cardiovascular disease","volume":"140","author":"C Welsh","year":"2019","journal-title":"Circulation"},{"key":"pone.0345032.ref031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"PS Jellinger","year":"2017","journal-title":"Endocr Pract"},{"issue":"21","key":"pone.0345032.ref032","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1161\/CIRCULATIONAHA.118.034273","article-title":"Long-term association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease","volume":"138","author":"SM Abdullah","year":"2018","journal-title":"Circulation"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0345032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T17:34:16Z","timestamp":1786642456000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0345032"}},"subtitle":[],"editor":[{"given":"Surya Prakash","family":"Bhatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0345032","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}